Pulmonary capillary hemangiomatosis (PCH) and pulmonary veno-occlusive disease (PVOD) are rare causes of primary pulmonary hypertension in humans, and, in 2016, were reported to occur in dogs. 16 PCH is characterized by widespread proliferation of thin-walled capillaries within the pulmonary parenchyma, including alveolar septa, and bronchiolar and perivascular interstitium. 6 PVOD is characterized by remodeling and occlusion of pulmonary venous vasculature by fibrosis and/or recanalization. 6 PCH may be a secondary change of PVOD, and although both are reported as primary disease processes, the clinicopathologic presentation of both diseases frequently overlaps. 6 The prognosis for both PVOD and PCH is generally poor, 9 and the cause of PVOD and/or PCH in humans and dogs is unknown. In humans, proposed contributing factors include left-sided congestive heart failure, inflammation, infectious agents, and genetics. 2, 4, 7, 8, 10 Elucidating the pathogeneses of these rare conditions in humans may benefit from the identification and characterization of spontaneous occurrences of PCH and/or PVOD in domestic species. We detail gross and histopathologic features consistent with PCH and PVOD in a domestic cat.
. Left thorax of a cat with pulmonary capillary hemangiomatosis. The lungs were rubbery-to-firm, and mottled red-to-dark-red and glistening. Cardiomegaly was marked. On section, there were numerous moderately well-demarcated, darkred foci (arrowheads, inset) throughout the parenchyma of all lung lobes. range: 5.0-12.0 mm; right ventricular free wall, 3 mm, reference range: 1.3-3.2 mm). 5 The left atrium was subjectively mildly dilated. There were no other significant gross abnormalities. Hypertrophic cardiomyopathy with left-sided congestive heart failure was considered as a primary differential diagnosis for cause of death given the marked left-sided cardiomegaly.
Tissue sections from lung, liver, kidney, spleen, heart, adrenal glands, thyroid glands, urinary bladder, pancreas, esophagus, trachea, stomach, small intestine, colon, and brain were fixed in 10% neutral-buffered formalin. The tissues were routinely processed and paraffin-embedded. Tissue sections of 5-μm thickness were cut onto slides and stained with hematoxylin and eosin. Lung sections were also stained with Verhoeff-van Gieson (VVG) elastin histochemical stain to identify veins, noted by the presence of only a thin, external elastic lamina. Immunohistochemical labeling of endothelial cells was performed on lung sections using a mouse monoclonal anti-CD31 antibody (clone JC70A; Dako North America, Carpinteria, CA).
Histologically, there was multifocal, widespread, mild-tomarked expansion of pulmonary alveolar septa by numerous, densely arranged, thin-walled congested capillaries lined by flattened, well-differentiated endothelial cells with minimal anisocytosis and anisokaryosis, affecting ~10-50% of the pulmonary parenchyma in all sections examined. The proliferating capillaries formed large expansive nodular foci, corresponding to the grossly described red, firm foci, which replaced the alveolar pulmonary parenchyma (Fig. 2 ). Proliferative capillaries multifocally infiltrated the interstitium along smooth muscle bundles and extended around the walls of respiratory bronchioles and small vessels. There was strong membranous CD31 labeling of endothelial cells within the proliferative thin-walled capillaries throughout alveolar septa and peribronchiolar interstitium ( Fig. 3 ). Affected regions of lung contained focally extensive hemorrhage, fibrin, and necrosis, with accumulations of fewto-moderate numbers of hemosiderin-laden macrophages. Diffusely, there were moderate numbers of foamy macrophages within alveolar spaces (alveolar histiocytosis). Additionally, rare veins and venules, identified using VVG elastin stain, had mural remodeling and occlusion by intraluminal fibrous stroma with one to several endothelial cell-lined vascular spaces ( Fig. 4) , congruent with PVOD. Additional microscopic findings included left-sided ventricular cardiac myofiber disarray and mild-to-moderate multifocal interstitial myocardial fibrosis ( Fig. 5 ). Significant morphologic changes were not identified in the additional tissues examined.
The cause of death was presumed to be multifactorial and likely the result of concurrent hypertrophic cardiomyopathy and severe primary pulmonary vasoproliferative disease, consistent with PCH. Therefore, in the absence of a detailed clinical history, we cannot rule out that the PCH contributed significantly to the death of this cat.
PCH and PVOD are rare causes of pulmonary hypertension in humans, and are associated with a poor prognosis. In humans, PCH and PVOD are diagnosed in patients ranging in age from infant to elderly. The major presenting clinical sign is dyspnea, although acute death is also reported and may be associated with right-sided heart failure, hypoxia, or respiratory failure. 1, 6 PCH and PVOD are clinically indistinguishable, and histopathology (biopsy or autopsy) remains the definitive diagnostic test for these 2 entities. 7,10 PVOD and PCH were identified for the first time in a small animal domestic species in a cohort of 11 dogs in 2016. 16 Affected dogs were generally older (median age: 10.5 y), and had rapidly progressive respiratory signs characterized by dyspnea, cyanosis, and pulmonary edema. Diagnosis of PVOD and PCH was primarily based on histopathologic, and not clinical, features. Although PCH has not been described in large animal domestic species, regional PVOD has been reported and is implicated as a possible contributing factor in exercise-induced pulmonary hemorrhage in horses. 15 In our case, the cat was ~1 y of age and reportedly showed no clinical signs prior to death. In the absence of extensive clinical investigation and given the lack of previous clinical signs, we are uncertain if this cat had overt clinical signs similar to those reported with PCH and PVOD in humans and dogs.
The grossly described left-sided cardiomegaly and microscopically apparent cardiac myofiber disarray and fibrosis in this cat were consistent with hypertrophic cardiomyopathy. There are reports of concurrent hypertrophic cardiomyopathy and PCH in humans, although the pathogenesis and relationship is unclear. In one report, the authors proposed a pathogenesis of chronic left-sided congestive heart failure resulting in reactive pulmonary vascular proliferation. 4 In another, congenital PCH was diagnosed in a stillborn fetus with concurrent HCM. 11 Various pulmonary vascular changes may manifest as a result of chronic leftsided congestive heart failure (CHF) in humans. 3 When severe and protracted, left-sided CHF may lead to vascular damage and vascular and interstitial remodeling, including interstitial collagen deposition, capillary proliferation, pulmonary arteriole and arterial intimal thickening, mural hypertrophy, and luminal obliteration. 12, 14 Hypertrophic cardiomyopathy is a well-documented feline cardiomyopathy, yet there are no reported associations of vasoproliferative pulmonary lesions and feline HCM. Therefore, the significance and relationship of concurrent HCM and PCH in this cat is unknown. We favor interpretation of the PCH in this cat as unrelated to the concurrent HCM based on the absence of pulmonary edema indicative of prolonged pulmonary venous hypertension.
Features of both PVOD and PCH frequently occur together in humans, and some have speculated that PCH represents an abortive angioproliferative process secondary to PVOD. 6 There appears to be a similar concurrence of PCH and PVOD lesions in dogs. 16 In our case, PCH was the predominant pattern in all lung sections examined, with nodular-to-widespread interstitial capillary proliferation. Rare remodeling was observed in several pulmonary veins and venules in this cat, resulting in near total obliteration of vascular lumina. These severe foci of venous remodeling are consistent with PVOD. Alternatively, we cannot rule out that pulmonary venous hypertension and blood stasis could have resulted in venous thrombosis, leading to these obliterative veno-occlusive lesions. The rarity of lesions of PVOD suggests that the extensive PCH in this cat is unlikely to be secondary to PVOD. These 2 disease processes were previously categorized into different groups, distinct from pulmonary arterial hypertension (PAH). The classification scheme was revised in 2013, with PCH and PVOD categorized together under the subgroup of PAH, 13 perhaps representing the common concurrence of and clinicopathologic similarities of these disease processes. PVOD and PCH are considered to be extremely rare causes of PAH in humans, only accounting for ~10% of unexplained cases of PAH. 13 The incidence of PVOD and PCH in veterinary species is unknown at this time. Until 2016, this was not documented to occur in domestic species, and therefore, may have been overlooked and/or misdiagnosed. In the 2016 canine case series, 2 of the 11 cases were originally clinically misdiagnosed as chronic CHF. 16 General awareness of PCH and PVOD within the veterinary community is imperative to better diagnose, ascertain incidence and pathogenesis, and potentially direct treatment of these rare diseases. The identification of PCH and PVOD in multiple domestic species may lead to valuable comparative models for PCH and PVOD.
